1 / 11

欢 迎 光 临

欢 迎 光 临. NCCN Clinical Practice Guidelines in Oncology™. Melanoma. Lili Yun nan biotherapy center 2008.1.10. Overview. In the year 2007, an estimated 59,940 new cases of melanoma will be diagnosed and about 8,110 patients will die of the disease in the United States.

oralee
Télécharger la présentation

欢 迎 光 临

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 欢 迎 光 临

  2. NCCN Clinical Practice Guidelines in Oncology™ Melanoma Lili Yun nan biotherapy center 2008.1.10

  3. Overview • In the year 2007, an estimated 59,940 new cases of melanoma will be diagnosed and about 8,110 patients will die of the disease in the United States. • The incidence of melanoma continues to increase dramatically. • The median age at diagnosis is 45 to 55 years.

  4. Risk factors for melanoma include strong family history, pigmented lesions, multiple clinically atypical moles and inherited genetic mutations. • prognostic factors include: • Tumor burden (expressed as the number of positive nodes); • Macroscopic (clinically apparent) or microscopic (clinically occult) nodal involvement; • the presence of extra－nodal soft-tissue extension; • primary tumor ulceration.

  5. Management of Metastatic Melanoma • Dacarbazine still remains a standard of care in community practice. • High dose intravenous bolus IL-2 treatment. • Combination chemotherapy regimens such as CVD(dacarbazine plus cisplatin and vinblastine) or Dartmouth regimen (dacarbazine, carmustine, cisplatin and tamoxifen)

  6. Biochemotherapy is the combination of chemotherapy and biological agents. CVD biochemotherapy (cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2)

  7. Thank you! Thank You

More Related